CHMP2B and frontotemporal dementia: These findings are consistent with motor-deficits in a recently reported transgenic CHMP2BIntron5 mouse model that drives expression using the neuronal Thy1.2 promoter (49), as well as the presence of motor symptoms at late stages of disease in patients with CHMP2B-FTD (29).